Somatic Genetic Testing Market Report 2026

The somatic genetic testing market size has grown rapidly in recent years. It will grow from $7.78 billion in 2025 to $8.88 billion in 2026 at a compound annual growth rate (CAGR) of 14.1%. The growth in the historic period can be attributed to limited access to genetic testing, reliance on conventional diagnostic methods, growing awareness of somatic mutations in cancer, increasing hospital and clinical laboratory infrastructure, rising investment in research institutes.

The somatic genetic testing market size is expected to see rapid growth in the next few years. It will grow to $14.92 billion in 2030 at a compound annual growth rate (CAGR) of 13.9%. The growth in the forecast period can be attributed to advancements in ngs and multi-omics technologies, expansion of at-home and clinical sequencing services, increasing precision medicine initiatives, rising government funding for genetic testing programs, integration of ai-based analytics for mutation interpretation. Major trends in the forecast period include rising adoption of targeted gene panels for cancer and rare diseases, increasing use of next-generation sequencing (ngs) technologies, growth in personalized and precision oncology treatments, expansion of at-home genetic testing solutions, integration of multi-omics data for clinical decision-making.

The escalating cancer incidence is poised to drive the somatic genetic testing market forward. Cancer encompasses disorders defined by rampant, spreading abnormal cells throughout the body. This growing burden stems from lifestyle factors like suboptimal nutrition, tobacco use, lack of exercise, and heavy drinking. Somatic genetic testing supports cancer diagnosis by pinpointing tumor-specific mutations, facilitating precise, individualized therapies. It curbs invasive methods through cutting-edge tools, enhancing detection reliability and patient results. For example, in November 2023, the Canadian Cancer Society, a Canada-based national cancer organization, projected 239,100 new diagnoses and about 86,700 deaths in 2023. Thus, the rising cancer incidence is fueling the somatic genetic testing market.

Prominent companies in the somatic genetic testing market are advancing diagnostic tools like liquid biopsy tests to sharpen precision, enable early spotting, and sidestep invasive steps. Liquid biopsy tests offer non-surgical analysis of circulating tumor DNA (ctDNA) or biomarkers in blood to uncover cancer-linked mutations. For instance, in September 2024, Strand Life Sciences, an India-based genomics and bioinformatics firm, introduced the Somatic Advantage 74 Liquid Biopsy (SA74 LB) test, a state-of-the-art liquid biopsy for ctDNA detection from blood. This NGS-driven assay scans somatic alterations in 74 critical cancer genes. It empowers tailored oncology by flagging treatable mutations, tracking therapy effects, and spotting minimal residual disease (MRD) minus tissue sampling. The test guides targeted drugs and real-time progression or resistance surveillance.

In June 2023, Genomenon Inc., a US healthcare tech company, acquired Boston Genetics Inc. for an undisclosed sum. This merger amplifies Genomenon's goal to map the full human genome by fusing its AI-driven Mastermind platform with Boston Genetics’ expert team, elevating genomic analysis for clinical testing and drug development. Boston Genetics Inc. is a US genomics firm expert in variant curation and annotation via specialist geneticists.

Major companies operating in the somatic genetic testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., QIAGEN N.V., Exact Sciences Corp., ARUP Laboratories Inc., Natera Inc., Myriad Genetics Inc., Fulgent Genetics Inc., Invitae Corporation, NeoGenomics Laboratories Inc., Guardant Health Inc., MedGenome Labs Ltd., Caris Life Sciences Inc., Oxford Nanopore Technologies Ltd., Pacific Biosciences of California Inc., Invivoscribe Inc., Centogene N.V., Circulogene Theranostics LLC.

North America was the largest region in the somatic genetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the somatic genetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the somatic genetic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the somatic genetic testing market by increasing costs of imported sequencing instruments, reagents, and consumables used in PCR, NGS, and microarray technologies. Segments like whole genome sequencing and targeted gene panels are most affected, particularly in North America and Europe, which rely heavily on imported high-tech equipment. This has resulted in higher operational costs and potential delays in testing services. On the positive side, tariffs have encouraged local manufacturing, investment in domestic sequencing infrastructure, and development of cost-efficient testing solutions.

The somatic genetic testing market research report is one of a series of new reports that provides somatic genetic testing market statistics, including somatic genetic testing industry global market size, regional shares, competitors with a somatic genetic testing market share, detailed somatic genetic testing market segments, market trends and opportunities, and any further data you may need to thrive in the somatic genetic testing industry. This somatic genetic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Somatic genetic testing involves the detailed analysis of genetic mutations that develop in non-reproductive (somatic) cells during a person’s lifetime, most commonly in tumor tissues. This testing is essential in cancer diagnosis and treatment, as it identifies specific genetic alterations that can be targeted with personalized therapies, helping to predict disease progression and guide clinical decisions.

The main types of somatic genetic testing are targeted gene panels, whole exome sequencing, whole genome sequencing, carrier screening, and others. Targeted gene panels focus on analyzing a specific set of genes linked to a particular disease or condition, enabling precise and cost-effective diagnosis. Samples for testing include tissue-based, blood-based, bone marrow aspirates, and others, utilizing advanced technologies such as polymerase chain reaction (PCR), next-generation sequencing (NGS), microarray, Sanger sequencing, and more. This testing is applied in cancer diagnosis, cardiovascular disorders, neurological disorders, inherited genetic disorders, and other areas, serving end users such as hospitals, clinical laboratories, research institutes, at-home testing providers, and more.

The somatic genetic testing market consists of revenues earned by entities by providing services such as tumor profiling, biomarker identification, companion diagnostic testing, mutation analysis, and next-generation sequencing (NGS) for personalized cancer therapy selection and treatment monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The somatic genetic testing market also includes sales of testing kits, reagents, assay panels, sequencing instruments, software tools for data analysis, and laboratory consumables used in the detection and interpretation of somatic mutations. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.